Nanjing, China

Lei Miao

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lei Miao. Retrieved from https://idiyas.com/inventor/lei-miao-mghkrssv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lei Miao - Innovator in Pharmaceutical Composition

Introduction

Lei Miao is a notable inventor based in Nanjing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug compositions. His work focuses on enhancing the efficacy of treatments through precise formulations.

Latest Patents

Lei Miao holds 1 patent for a unit dosage composition of an AKT inhibitor. This patent specifically relates to a pharmaceutical composition in unit dosage form that includes a compound of formula I-0 or a pharmaceutically acceptable salt thereof. The formulation is designed to contain a mass of the compound I-0 or its salt ranging from 5 mg to 400 mg, calculated as free base.

Career Highlights

Miao is currently employed at Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. His role at the company allows him to apply his expertise in pharmaceutical development and contribute to the advancement of medical treatments.

Collaborations

Some of his coworkers include Ying Tang and He Tian, who collaborate with him on various projects within the pharmaceutical sector.

Conclusion

Lei Miao's innovative work in pharmaceutical compositions exemplifies the impact of targeted research and development in medicine. His contributions are paving the way for more effective treatments in the healthcare industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…